<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02134054</url>
  </required_header>
  <id_info>
    <org_study_id>SUSI-CS_1</org_study_id>
    <nct_id>NCT02134054</nct_id>
  </id_info>
  <brief_title>Stavanger IBD Study - Cross Sectional</brief_title>
  <acronym>SUSI-CS</acronym>
  <official_title>Stavanger University Hospital IBD Study - a Cross Sectional Longitudinal Study on Patients Treated With Biologics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Stavanger HF</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Helse Stavanger HF</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this cross sectional and longitudinal study, patients with inflammatory bowel disease on
      biological treatment with infliximab or adalimumab will be included.

      After inclusion, the dosage of their existing biological therapy will be adjusted following
      regular trough-level and antibody-level monitoring, according to a treatment algorithm.

      Disease activity markers, fatigue and QoL will be assessed during the study. The hypothesis
      is that therapeutic drug monitoring may improve clinical disease outcome after one year of
      follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">November 2020</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical remission rate</measure>
    <time_frame>One Year</time_frame>
    <description>Harvey Bradshaw Index &lt;5 Partial Mayo score &lt;=2</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptom scoring</measure>
    <time_frame>One Year</time_frame>
    <description>Harvey Bradshaw Index, Partial Mayo Score. Change after therapeutic drug monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers</measure>
    <time_frame>One year</time_frame>
    <description>C reactive protein, Fecal Calprotectin. Change after therapeutic drug monitoring.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue scoring</measure>
    <time_frame>One Year</time_frame>
    <description>Assessed by Fatigue severity scale and Visual analogue scale. Change after therapeutic drug monitoring.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Healthcare resource utilization</measure>
    <time_frame>One year</time_frame>
    <description>Registration of
Outpatient visits
Hospital admissions (days)
Sick leave (days)
Visits at general practitioner due to IBD activity
Endoscopy due to IBD activity</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">210</enrollment>
  <condition>Inflammatory Bowel Disease</condition>
  <arm_group>
    <arm_group_label>Biologic</arm_group_label>
    <description>Patients on treatment with biologics (infliximab or adalimumab)</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Standard blood sampling Serum sampling - trough/antibodies of biological agent
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with inflammatory bowel disease established (minimum 3 doses) on treatment with
        infliximab or adalimumab
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with inflammatory bowel disease on treatment with infliximab or
             adalimumab of any duration (at least 3 doses)

        Exclusion Criteria:

          -  Inability to consent

          -  Inability to adhere to treatment protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tore B Grimstad, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stavanger University Hospital, Department of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stavanger University Hospital</name>
      <address>
        <city>Stavanger</city>
        <zip>4068</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 29, 2014</study_first_submitted>
  <study_first_submitted_qc>May 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2014</study_first_posted>
  <last_update_submitted>December 4, 2017</last_update_submitted>
  <last_update_submitted_qc>December 4, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Therapeutic drug monitoring</keyword>
  <keyword>Biological treatment</keyword>
  <keyword>IBD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

